An open-label phase I-II trial studied rilzabrutinib (second generation BTK inhibitor) in patients with immune thrombocytopenia (ITP), an immune cytopenia similar to AIHA. This evidence concerns the gene BTK and autoimmune thrombocytopenic purpura.